Document Detail


The impact of pharmacogenetics for migraine.
MedLine Citation:
PMID:  11173058     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Migraine is a paroxysmal neurological disorder affecting up to 12% of males and 24% of females in the general population. As migraine has been demonstrated to have a strong, but complex, genetic component, pharmacogenetics bears great promise in providing new targets for drug development and optimization of individual specific therapy. Better, preferably prophylactic, treatment of migraine patients is desired because the drugs now used are not effective in all patients, allow recurrence of the headache in a high percentage of patients and sometimes have severe adverse side-effects. With the recent identification of the brain-specific P/Q-type Ca(2+)channel gene CACNA1A as a pivotal player in the pathogenesis of migraine, the first step has been taken to identify primary biochemical pathways leading to migraine. The work on migraine can also have implications for the increasing number of additional neurological episodic disorders having the common denominator of channelopathy.
Authors:
R A Ophoff; A M van den Maagdenberg; K I Roon; M D Ferrari; R R Frants
Related Documents :
17157688 - Hypertrophic cardiomyopathy: electrocardiographic manifestations and other important co...
8667388 - Parity diagnosis and ovulation in culiseta inornata (diptera:culicidae).
19614688 - Temporomandibular disorders and cutaneous allodynia are associated in individuals with ...
8496058 - Episodic paroxysmal hemicrania: 3 new cases and a review of the literature.
8745388 - Infantile onset of hereditary ascending spastic paralysis with bulbar involvement.
16816788 - Insight in body dysmorphic disorder with and without comorbid obsessive-compulsive diso...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European journal of pharmacology     Volume:  413     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-02-22     Completed Date:  2001-07-12     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1-10     Citation Subset:  IM    
Affiliation:
MGC-Department of Human and Clinical Genetics, Leiden University Medical Center, Wassenaarseweg 72, 2333 AL Leiden, Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Calcium Channel Blockers / therapeutic use
Calcium Channels / genetics,  metabolism
Chromosomes, Human, Pair 19 / genetics
Ergot Alkaloids / therapeutic use
Humans
Migraine Disorders / drug therapy*,  genetics*,  physiopathology,  prevention & control
Mutation
Pharmacogenetics* / trends
Receptors, Dopamine D2 / genetics
Sumatriptan / therapeutic use
Valproic Acid / therapeutic use
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/CACNA1A protein, human; 0/Calcium Channel Blockers; 0/Calcium Channels; 0/Ergot Alkaloids; 0/Receptors, Dopamine D2; 103628-46-2/Sumatriptan; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Creating discrete joint densities from continuous ones: the moment matching-maximum entropy approach...
Next Document:  Pharmacogenomics of neurodegenerative diseases.